Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression

Ma,Juan; Chen,Meng; Xia,Shu-Kai; Shu,Wei; Guo,Yan; Wang,Yao-Hui; Xu,Yan; Bai,Xiao-Ming; Zhang,Li; Zhang,Hai; Zhang,Min; Wang,Yi-Pin; Leng,Jing

doi:10.3892/ijo.2013.1782

Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression

Authors:
- Juan Ma
- Meng Chen
- Shu-Kai Xia
- Wei Shu
- Yan Guo
- Yao-Hui Wang
- Yan Xu
- Xiao-Ming Bai
- Li Zhang
- Hai Zhang
- Min Zhang
- Yi-Pin Wang
- Jing Leng
View Affiliations

Affiliations: Cancer Center, Department of Pathology, Nanjing Medical University, Nanjing 210029, P.R. China, Stomatology Research Institute, Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing 210029, P.R. China, Institute of Pediatrics of the Fourth Clinical College, Nanjing Medical University, Nanjing 210029, P.R. China, Department of Pathology, TCM Hospital of Jiangsu Province, Nanjing 210029, P.R. China
Published online on: January 18, 2013 https://doi.org/10.3892/ijo.2013.1782
Pages: 1093-1104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is a common human cancer with a high mortality rate and currently there is no effective chemoprevention or systematic treatment. Recent evidence suggests that prostaglandin E2 (PGE2) plays an important role in the occurrence and development of liver cancer. However, the mechanisms through which PGE2 promotes liver cancer cell growth are not yet fully understood. It has been reported that the increased expression of FUSE-binding protein 1 (FBP1) significantly induces the proliferation of liver cancer cells. In this study, we report that PGE2 promotes liver cancer cell growth by the upregulation of FBP1 protein expression. Treatment with PGE2 and the E prostanoid 3 (EP3) receptor agonist, sulprostone, resulted in the time-dependent increase in FBP1 protein expression; sulprostone increased the viability of the liver cancer cells. The protein kinase A (PKA) inhibitor, H89, and the adenylate cyclase (AC) inhibitor, SQ22536, inhibited the cell viability accelerated by sulprostone. By contrast, the Gi subunit inhibitor, pertussis toxin (PTX), exhibited no significant effect. Treatment with PGE2 and sulprostone caused a decrease in JTV1 protein expression, blocked the binding of JTV1 with FBP1, which served as a mechanism for FBP1 degradation, leading to the decreased ubiquitination of FBP1 and the increase in FBP1 protein expression. Furthermore, H89 and SQ22536 prevented the above effects of JTV1 and FBP1 induced by PGE2 and sulprostone. These findings indicate that the EP3 receptor activated by PGE2 may couple to Gs protein and activate cyclic AMP (cAMP)-PKA, downregulating the levels of JTV1 protein, consequently inhibiting the ubiquitination of FBP1 and increasing FBP1 protein expression, thus promoting liver cancer cell growth. These observations provide new insights into the mechanisms through which PGE2 promotes cancer cell growth.

View Figures

View References

1	LeBlanc MM, Giguère S, Lester GD, Brauer K and Paccamonti DL: Relationship between infection, inflammation and premature parturition in mares with experimentally induced placentitis. Equine Vet J. (Suppl)41:8–14. 2012. View Article : Google Scholar
2	Menter DG and Dubois RN: Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol. 2012:7234192012. View Article : Google Scholar : PubMed/NCBI
3	Granado-Serrano AB, Martín MÁ, Bravo L, Goya L and Ramos S: Quercetin attenuates TNF-induced inflammation in hepatic cells by inhibiting the NF-κB pathway. Nutr Cancer. 4:588–598. 2012.PubMed/NCBI
4	Sasaki Y, Kamei D, Ishikawa Y, et al: Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene. 24:2943–2952. 2012. View Article : Google Scholar : PubMed/NCBI
5	Thiel A, Narko K, Heinonen M, et al: Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int J Cancer. 131:1032–1041. 2012. View Article : Google Scholar : PubMed/NCBI
6	Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M and Thill M: Impact of cyclooxygenase-2 in breast cancer. Anticancer Res. 12:4359–4367. 2011.PubMed/NCBI
7	Nadda N, Vaish V, Setia S and Sanyal SN: Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 66:474–483. 2012. View Article : Google Scholar : PubMed/NCBI
8	Smith KA, Tong X, Abu-Yousif AO, Mikulec CC, Gottardi CJ, Fischer SM and Pelling JC: UVB radiation-induced β-catenin signaling is enhanced by COX-2 expression in keratinocytes. Mol Carcinog. 51:734–745. 2012.
9	Phutthaphadoong S, Yamada Y, Hirata A, et al: Chemopreventive effect of fermented brown rice and rice bran (FBRA) on the inflammation-related colorectal carcinogenesis in Apc^Min/+ mice. Oncol Rep. 1:53–59. 2010.PubMed/NCBI
10	Bai XM, Jiang H, Ding JX, et al: Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sci. 86:214–223. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Jiang L, Sun QY, Peng T, Lou KX, Liu NB and Leng J: Prostaglandin E2 enhances mitogenactivated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. Mol Cell Biochem. 305:19–26. 2007. View Article : Google Scholar
12	Wu T: Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta. 1775:135–150. 2005.
13	Kotelevets L, Foudi N, Louedec L, Couvelard A, Chastre E and Norel X: A new mRNA splice variant coding for the human EP3-I receptor isoform. Prostaglandins Leukot Essent Fatty Acids. 77:195–201. 2007. View Article : Google Scholar : PubMed/NCBI
14	Regan JW, Bailey TJ, Donello JE, et al: Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br J Pharmacol. 112:377–385. 1994. View Article : Google Scholar : PubMed/NCBI
15	Schmid A, Thierauch KH, Schleuning WD and Dinter H: Splice variants of the human EP3 receptor for prostaglandin E₂. Eur J Biochem. 228:23–30. 1995. View Article : Google Scholar : PubMed/NCBI
16	Kotani M, Tanaka I, Ogawa Y, et al: Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol. 48:869–879. 1995.
17	Kotani M, Tanaka I, Ogawa Y, et al: Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus. J Clin Endocrinol Metab. 85:4315–4322. 2000. View Article : Google Scholar : PubMed/NCBI
18	Israel DD and Regan JW: EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation. Biochim Biophys Acta. 4:238–245. 2009. View Article : Google Scholar : PubMed/NCBI
19	Rydziel S, Delany AM and Canalis E: AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts. J Biol Chem. 279:5397–5404. 2004. View Article : Google Scholar : PubMed/NCBI
20	Malz M, Weber A, Singer S, et al: Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology. 50:1130–1139. 2009. View Article : Google Scholar : PubMed/NCBI
21	Weber A, Kristiansen I, Johannsen M, et al: The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer. 8:3692008. View Article : Google Scholar : PubMed/NCBI
22	Chung HJ, Liu J, Dundr M, Nie Z, Sanford S and Levens D: FBPs are calibrated molecular tools to adjust gene expression. Mol Cell Biol. 26:6584–6597. 2006. View Article : Google Scholar : PubMed/NCBI
23	Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, et al: Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology. 4:1121–1129. 2009. View Article : Google Scholar : PubMed/NCBI
24	Andersen SS: Spindle assembly and the art of regulating micro-tubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol. 10:261–267. 2000. View Article : Google Scholar : PubMed/NCBI
25	Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, Kuner R, Huber P, Schirmacher P and Breuhahn K: Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res. 6:2234–2243. 2009. View Article : Google Scholar
26	He LS, Liu JH, Collins I, et al: Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J. 5:1034–1044. 2000.PubMed/NCBI
27	Liu J, Kouzine F, Nie Z, et al: The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J. 10:2119–2130. 2006. View Article : Google Scholar : PubMed/NCBI
28	Avigan MI, Strober B and Levens D: A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem. 30:18538–18545. 1990.PubMed/NCBI
29	Hsiao HH, Nath A, Lin CY, et al: Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry. 49:4620–4634. 2010. View Article : Google Scholar : PubMed/NCBI
30	Wierstra I and Alves J: The c-myc promoter: still MysterY and challenge. Adv Cancer Res. 99:113–333. 2008. View Article : Google Scholar : PubMed/NCBI
31	Jang M, Park BC, Kang S, et al: Far upstream element-binding protein-1, a novel caspase ubstrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene. 28:1529–1536. 2009. View Article : Google Scholar : PubMed/NCBI
32	Wang X, Avigan M and Norgren RB: FUSE-binding protein is developmentally regulated and is highly expressed in mouse and chicken embryonic brain. Neurosci Lett. 252:191–194. 1998. View Article : Google Scholar : PubMed/NCBI
33	Ko HS, Kim SW, Sriram SR, Dawson VL and Dawson TM: Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem. 281:16193–16196. 2006. View Article : Google Scholar : PubMed/NCBI
34	Duncan RD, Bazar L, Michelotti G, et al: A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes. 8:465–480. 1994. View Article : Google Scholar : PubMed/NCBI
35	Bazar L, Harris V, Sunitha I, Hartmann D and Avigan MI: A transactivator of c-myc is coordinately regulated with the protooncogene during cellular growth. Oncogene. 10:2229–2238. 1995.PubMed/NCBI
36	Yamaki T, Endoh K, Miyahara M, et al: Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Cancer Lett. 214:115–120. 2004. View Article : Google Scholar : PubMed/NCBI
37	Yutaka S, Mami T, Nobuo T, et al: Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. Carcinogenesis. 26:2116–2122. 2005. View Article : Google Scholar : PubMed/NCBI
38	Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M and Donnini S: Prostaglandin E₂ regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem. 283:2139–2146. 2008.
39	Gutierrez DV, Mark MD, Masseck O, et al: Optogenetic control of motor coordination by G_i/_o protein-coupled vertebrate rhodopsin in cerebellar Purkinje cells. J Biol Chem. 286:25848–25858. 2011. View Article : Google Scholar : PubMed/NCBI
40	Deng J, Liu S, Zou L, Xu C, Geng B and Xu G: Lipolysis response to endoplasmic reticulum stress in adipose cells. J Biol Chem. 287:6240–6249. 2012. View Article : Google Scholar : PubMed/NCBI
41	McCarthy TL, Pham TH, Knoll BI and Centrella M: Prostaglandin E₂ increases transforming growth factor-β type III receptor expression through CCAAT enhancer-binding protein δ in osteoblasts. Mol Endocrinol. 11:2713–2724. 2007.PubMed/NCBI
42	Massague J, Blain SW and Lo RS: TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 103:295–309. 2000. View Article : Google Scholar : PubMed/NCBI
43	Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
44	Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol. 11:S44–S51. 2001.PubMed/NCBI
45	Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
46	Wakefield LM and Roberts AB: Learning together: clinical skills teaching for medical and nursing students. Curr Opin Genet. 12:22–29. 2002.
47	Pierce DF Jr, Johnson MD, et al: Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev. 7:2308–2317. 1993. View Article : Google Scholar : PubMed/NCBI
48	Cui W, Fowlis DJ, Bryson S, et al: TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 86:531–542. 1996. View Article : Google Scholar : PubMed/NCBI
49	Bottinger EP, Jakubczak JL, Haines DC, Bagnall K and Wakefield LM: Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 57:5564–5570. 1997.
50	Gorska AE, Joseph H, Derynck R, Moses HL and Serra R: Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ. 9:229–238. 1998.
51	Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS and Doetschman T: Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 59:3379–3386. 1999.PubMed/NCBI
52	Zhu Y, Richardson JA, Parada LF and Graff JM: Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:703–714. 1998. View Article : Google Scholar : PubMed/NCBI
53	Xu X, Brodie SG, Yang X, et al: Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene. 19:1868–1874. 2000. View Article : Google Scholar : PubMed/NCBI
54	Tang B, Bottinger EP, Jakowlew SB, et al: Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med. 4:802–807. 1998. View Article : Google Scholar : PubMed/NCBI
55	Han C, Demetris AJ, Liu Y, Shelhamer JH and Wu T: Transforming growth factor-β (TGF-β) activates cytosolic phospholipase A₂α (cPLA2α)-mediated prostaglandin E₂ (PGE)2/EP1 and peroxisome proliferator-activated receptor-γ (PPAR-γ)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-β-induced mitoinhibition. J Biol Chem. 43:44344–44354. 2004.
56	Markowitz SD, Itzkowitz SH and Berger BM: The effectiveness of colonoscopy in reducing mortality from colorectal cancer. Ann Intern Med. 150:816–817. 2009. View Article : Google Scholar
57	Chowdhury S, Howell GM, Rajput A, et al: Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One. 5:e193352011.
58	Liu X, Sun S and Ostrom R: Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient cAMP response element-binding protein phosphorylation. J Pharmacol Exp Ther. 2:678–687. 2005. View Article : Google Scholar : PubMed/NCBI
59	Schiller M, Verrecchia F and Mauviel A: Cyclic adenosine 3′,5′,-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD¾-dependent transcription via a protein kinase A-dependent mechanism. Oncogene. 22:8881–8890. 2003.
60	Kim MJ, Park BJ, Kang YS, Kim HJ, Park JH and Kang JW: Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet. 34:330–336. 2003. View Article : Google Scholar : PubMed/NCBI
61	Kim JY, Kang YS, Lee JW, Kim HJ, Ahn YH, Park H, Ko YG and Kim S: p38 is essential for the assembly and stability of macromolecular tRNA synthetase complex: implications for its physiological significance. Proc Natl Acad Sci USA. 99:7912–7916. 2002. View Article : Google Scholar : PubMed/NCBI
62	Liu J, Chung HJ, Vogt M, et al: JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J. 30:846–858. 2011. View Article : Google Scholar : PubMed/NCBI
63	Sampath P, Mazumder B, Seshadri V, et al: Noncanonical function of glutamyl-prolyl-tRNA synthetase: genespecific silencing of translation. Cell. 119:195–208. 2004. View Article : Google Scholar : PubMed/NCBI
64	Park SG, Kang YS, Ahn YH, et al: Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis. J Biol Chem. 277:45243–45248. 2002. View Article : Google Scholar : PubMed/NCBI
65	Han JM, Park BJ, Park SG, et al: AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53. Proc Natl Acad Sci USA. 105:11206–11211. 2008. View Article : Google Scholar : PubMed/NCBI
66	Corti O, Hampe C, Koutnikova H, et al: p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet. 12:1427–1437. 2003. View Article : Google Scholar : PubMed/NCBI
67	Ko HS, Coelln R, Sriram SR, et al: Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci. 25:7968–7978. 2005. View Article : Google Scholar : PubMed/NCBI